Atreca, Inc. – NASDAQ:BCEL
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Atreca stock price monthly change
-5.26%
month
Atreca stock price quarterly change
-61.21%
quarter
Atreca stock price yearly change
-91.22%
year
Atreca key metrics
Market Cap | 3.56M |
Enterprise value | 68.43M |
P/E | -0.4 |
EV/Sales | N/A |
EV/EBITDA | -0.49 |
Price/Sales | N/A |
Price/Book | 0.45 |
PEG ratio | -0.03 |
EPS | -2.43 |
Revenue | 263K |
EBITDA | -54.00M |
Income | -95.07M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | -20533.46% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAtreca stock price history
Atreca stock forecast
Atreca financial statements
| Dec 2022 | 20K | -20.91M | -104575% |
|---|---|---|---|
| Mar 2023 | 92K | -18.76M | -20392.39% |
| Jun 2023 | 71K | -19.18M | -27022.54% |
| Sep 2023 | 80K | -36.21M | -45268.75% |
| 2027 | 16.66M | -28.94M | -173.67% |
|---|
Analysts Price target
Financials & Ratios estimates
| Dec 2022 | 155030000 | 76.62M | 49.43% |
|---|---|---|---|
| Mar 2023 | 134426000 | 73.46M | 54.65% |
| Jun 2023 | 115069000 | 70.39M | 61.18% |
| Sep 2023 | 26342000 | 15.58M | 59.16% |
| Dec 2022 | -15.43M | 25.34M | 0 |
|---|---|---|---|
| Mar 2023 | -14.44M | 23M | 109K |
| Jun 2023 | -17.98M | 6.18M | 1K |
| Sep 2023 | -17.21M | 2.99M | 9K |
Atreca alternative data
| Aug 2023 | 90 |
|---|---|
| Sep 2023 | 90 |
| Oct 2023 | 90 |
| Nov 2023 | 90 |
| Dec 2023 | 90 |
| Jan 2024 | 90 |
| Feb 2024 | 90 |
| Mar 2024 | 90 |
| Apr 2024 | 90 |
| May 2024 | 90 |
| Jun 2024 | 90 |
| Jul 2024 | 90 |
Atreca other data
11.56%
-25.75%
of BCEL is owned by hedge funds
29
-22
4.45M
-9.98M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Aug 2023 | 0 | 19126 |
| Oct 2023 | 0 | 274739 |
| Apr 2024 | 1 | 20788 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | ORWIN JOHN A director, officer.. | Series A Junior Preferred Stock | 1 | $0.01 | $0 | ||
Sale | SERAFINI TITO director | Class A Common Stock | 20,788 | $0.07 | $1,455 | ||
Sale | BAKER BROS. ADVISORS LP | Class A common stock | 251,902 | $0.4 | $101,517 | ||
Sale | BAKER BROS. ADVISORS LP | Class A common stock | 22,837 | $0.4 | $9,203 | ||
Sale | CROSS HERB officer: Chief Financial Officer | Class A Common Stock | 5,487 | $0.95 | $5,224 | ||
Sale | GOULD STEPHEN E officer: Chief Scientific Officer | Class A Common Stock | 4,076 | $0.95 | $3,880 | ||
Sale | COURTNEY PHILLIPS officer: General Counsel & Secr.. | Class A Common Stock | 4,076 | $0.95 | $3,880 | ||
Sale | SERAFINI TITO director, officer: Chief Strate.. | Class A Common Stock | 5,487 | $0.95 | $5,224 | ||
Sale | COURTNEY PHILLIPS officer: General Counsel & Secr.. | Class A Common Stock | 6,432 | $1.78 | $11,417 | ||
Sale | CROSS HERB officer: Chief Financial Officer | Class A Common Stock | 7,646 | $1.78 | $13,572 |
| Patent |
|---|
Application Filling date: 8 Apr 2022 Issue date: 4 Aug 2022 |
Application Filling date: 19 Feb 2020 Issue date: 23 Jun 2022 |
Application Filling date: 31 Jan 2022 Issue date: 19 May 2022 |
Application COMBINATORIAL SETS OF NUCLEIC ACID BARCODES FOR ANALYSIS OF NUCLEIC ACIDS ASSOCIATED WITH SINGLE CELLS Filling date: 28 Jul 2021 Issue date: 9 Dec 2021 |
Grant Filling date: 11 May 2018 Issue date: 20 Jul 2021 |
Application Filling date: 9 Sep 2020 Issue date: 11 Feb 2021 |
Application Filling date: 9 Sep 2020 Issue date: 11 Feb 2021 |
Application Filling date: 9 Apr 2020 Issue date: 12 Nov 2020 |
Application Filling date: 14 Feb 2020 Issue date: 15 Oct 2020 |
Application Filling date: 3 May 2019 Issue date: 23 Apr 2020 |
| Quarter | Transcript |
|---|---|
| Q4 2022 29 Mar 2023 | Q4 2022 Earnings Call Transcript |
| Q4 2021 4 Mar 2022 | Q4 2021 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. John A. Orwin (1965) Pres, Chief Executive Officer & Director | $863,520 |
Mr. Herbert C. Cross (1972) Chief Financial Officer | $591,570 |
-
When is Atreca's next earnings date?
Unfortunately, Atreca's (BCEL) next earnings date is currently unknown.
-
Does Atreca pay dividends?
No, Atreca does not pay dividends.
-
How much money does Atreca make?
Atreca has a market capitalization of 3.56M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 9.52% to 770K US dollars.
-
What is Atreca's stock symbol?
Atreca, Inc. is traded on the NASDAQ under the ticker symbol "BCEL".
-
What is Atreca's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Atreca?
Shares of Atreca can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Atreca's key executives?
Atreca's management team includes the following people:
- Mr. John A. Orwin Pres, Chief Executive Officer & Director(age: 60, pay: $863,520)
- Mr. Herbert C. Cross Chief Financial Officer(age: 53, pay: $591,570)
-
How many employees does Atreca have?
As Jul 2024, Atreca employs 90 workers.
-
When Atreca went public?
Atreca, Inc. is publicly traded company for more then 6 years since IPO on 20 Jun 2019.
-
What is Atreca's official website?
The official website for Atreca is atreca.com.
-
Where are Atreca's headquarters?
Atreca is headquartered at 835 Industrial Road, South San Francisco, CA.
-
How can i contact Atreca?
Atreca's mailing address is 835 Industrial Road, South San Francisco, CA and company can be reached via phone at +65 05952595.
Atreca company profile:
Atreca, Inc.
atreca.comExchange:
NASDAQ
Full time employees:
90
Industry:
Biotechnology
Sector:
Healthcare
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It also developing APN-122597, a receptor tyrosine kinase that target tumor tissues; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. Atreca, Inc. was incorporated in 2010 and is based in San Carlos, California.
835 Industrial Road
South San Francisco, CA 94070
South San Francisco, CA 94070
CIK: 0001532346
ISIN: US04965G1094
CUSIP: 04965G109
